scholarly journals Voluntary Running Attenuates Memory Loss, Decreases Neuropathological Changes and Induces Neurogenesis in a Mouse Model of Alzheimer's Disease

2015 ◽  
Vol 26 (1) ◽  
pp. 62-74 ◽  
Author(s):  
Cheril Tapia-Rojas ◽  
Florencia Aranguiz ◽  
Lorena Varela-Nallar ◽  
Nibaldo C. Inestrosa
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Memory Loss ◽  
Model Of Alzheimer’S Disease ◽  
Voluntary Running

scholarly journals Intranasal Delivery of NEMO-Binding Domain Peptide Prevents Memory Loss in a Mouse Model of Alzheimer’s Disease

2015 ◽  
Vol 47 (2) ◽  
pp. 385-402 ◽  
Author(s):  
Suresh B. Rangasamy ◽  
Grant T. Corbett ◽  
Avik Roy ◽  
Khushbu K. Modi ◽  
David A. Bennett ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Memory Loss ◽  
Binding Domain ◽  
Intranasal Delivery ◽  
Model Of Alzheimer’S Disease ◽  
Domain Peptide ◽  
Nemo Binding Domain

scholarly journals Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer's Disease

PLoS ONE ◽  
2015 ◽  
Vol 10 (11) ◽  
pp. e0142267 ◽  
Author(s):  
Marielza Andrade Nunes ◽  
Natalia Mendes Schöwe ◽  
Karla Cristina Monteiro-Silva ◽  
Ticiana Baraldi-Tornisielo ◽  
Suzzanna Ingryd Gonçalves Souza ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Transgenic Mouse ◽  
Lithium Treatment ◽  
Memory Loss ◽  
Transgenic Mouse Model ◽  
Model Of Alzheimer’S Disease

scholarly journals Correction: Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer's Disease

PLoS ONE ◽  
2015 ◽  
Vol 10 (12) ◽  
pp. e0145695 ◽  
Author(s):  
Marielza Andrade Nunes ◽  
Natalia Mendes Schöwe ◽  
Karla Cristina Monteiro-Silva ◽  
Ticiana Baraldi-Tornisielo ◽  
Suzzanna Ingryd Gonçalves Souza ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Transgenic Mouse ◽  
Lithium Treatment ◽  
Memory Loss ◽  
Transgenic Mouse Model ◽  
Model Of Alzheimer’S Disease

JBPOS0101 attenuates amyloid-β accumulation and memory loss in a mouse model of Alzheimer’s disease

Neuroreport ◽  
2019 ◽  
Vol 30 (10) ◽  
pp. 741-747
Author(s):  
Hyung Joon Park ◽  
Ju Kyong Jang ◽  
Yong Moon Choi ◽  
Won-Seok Choi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Memory Loss ◽  
Amyloid Β ◽  
Model Of Alzheimer’S Disease

scholarly journals The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer’s Disease

2020 ◽  
Vol 35 ◽  
pp. 153331752095304
Author(s):  
Mark Maskery ◽  
Elizabeth Mary Goulding ◽  
Simon Gengler ◽  
Josefine Ulrikke Melchiorsen ◽  
Mette Marie Rosenkilde ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Receptor Agonist ◽  
Neurodegenerative Disorder ◽  
Memory Loss ◽  
Amyloid Plaques ◽  
Model Of Alzheimer’S Disease ◽  
The Brain ◽  
Gip Receptor

Alzheimer’s disease (AD) is a neurodegenerative disorder for which there is no cure. Here, we test a dual GLP-1/GIP receptor agonist (DA4-JC) that has a cell penetrating sequence added to enhance blood-brain barrier penetration. We show in a receptor activity study that DA4-JC has balanced activity on both GLP-1 and GIP receptors but not on GLP-2 or Glucagon receptors. A dose-response study in the APP/PS1 mouse model of AD showed both a dose-dependent drug effect on the inflammation response and the reduction of amyloid plaques in the brain. When comparing DA4-JC with the GLP-1 analogue liraglutide at equal doses of 10nmol/kg bw ip. once-daily for 8 weeks, DA4-JC was more effective in reversing memory loss, enhancing synaptic plasticity (LTP) in the hippocampus, reducing amyloid plaques and lowering pro-inflammatory cytokine levels in the brain. The results suggest that DA4-JC may be a novel treatment for AD.

Sign in / Sign up

Export Citation Format

Share Document